Why the study?
Does immunization with beta1AR EC(II) peptide induce early stage cardiomyopathy in rats?
Does immunization with beta1AR EC(II) peptide induce early stage cardiomyopathy in rats?
Immunization of rats with a beta1AR EC(II) peptide induces early cardiomyopathic changes, supporting the pathogenic role of beta1AR autoantibodies in dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for beta1AR autoantibody pathogenicity in cardiomyopathy; extends preclinical models but leaves open human translation.
In the failing human heart, due to idiopathic dilated cardiomyopathy, it has been suggested that the beta1-adrenergic receptor (beta1AR) is a potential pathogenic autoantigen. The aim of the present study was to investigate whether immunization of rats with a synthetic peptide corresponding to the second extracellular loop of the beta1AR (beta1AR EC(II)) was able to induce the early stage of cardiomyopathy and also to investigate immunological and receptor functional parameters at a transcriptional level to permit insights into the autoimmune mechanism in cardiomyopathy. Eleven Whistar Fur rats were immunized with a beta1AR EC(II) peptide (H26R) once a month during 12 months and seven control rats were injected with vehicle according to the same procedure used for the immunized group. Cardiac function, beta1AR autoantibodies and their functional effects on cardiomyocytes were analysed. beta1AR receptor signalling, immunological and cardiomyocyte stretch markers were determined on transcriptional level. In H26R immunized rats, beta1AR autoantibodies were shown to be present and functionally active, cardiac functions in terms of fractional shortening were decreased and beta1-adrenergic receptor kinase (GRK2) mRNA were increased compared with the control group. These data have shown that immunization of rats with a putative antigenic peptide was able to induce an early stage phenotype of cardiomyopathy in the form of cardiac dysfunction and up-regulation of GRK2 as the first step in the desensitization process of the beta1AR, implying the pathological importance of the beta1AR autoantibody.
No takes yet. Share an insight, caveat, or question.
Buvall et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: